Skip to content
Home
About Us
Longevity Platform
Bio101
BIO101 in Sarcopenia
BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
Posters & Publications
Scientific Press Releases
Recruitment
Investors
Stock Information
Corporate Presentation
Letter to shareholders
Press Releases
General Meetings
AMF Regulated Information
SEC Filings
Convertible bonds
Pre-financed vouchers (PFW)
Obligations Hexagon
Contact for Investors
Contact
EN
FR
Blog Category
Other
Biophytis second AGM to take place on May 28, 2020 without the physical presence of its shareholders
Other
,
Press Releases
/
20 May 2020
Convening of another combined General Meeting at a Later Date
Other
,
Press Releases
/
11 May 2020
Biophytis AGM meeting will take place on May 11, 2020 without the physical presence of its shareholders
Other
,
Press Releases
/
30 April 2020
Protocol Amendment of SARA-INT, a Phase 2b Clinical Trial of Sarconeos (BIO101) in Sarcopenia, Cleared by FDA and AFMPS
Other
,
Press Releases
/
11 February 2020
←
1
2
3
Go to Top
Home
About Us
Longevity Platform
Bio101
BIO101 in Sarcopenia
BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
Posters & Publications
Scientific Press Releases
Recruitment
Investors
Stock Information
Corporate Presentation
Letter to shareholders
Press Releases
General Meetings
AMF Regulated Information
SEC Filings
Convertible bonds
Pre-financed vouchers (PFW)
Obligations Hexagon
Contact for Investors
Contact
EN
FR
Home
About Us
Longevity Platform
Bio101
BIO101 in Sarcopenia
BIO101 in Obesity
Biophytis Biopharmaceutical
Other Projects
Resources
Posters & Publications
Scientific Press Releases
Recruitment
Investors
Stock Information
Corporate Presentation
Letter to shareholders
Press Releases
General Meetings
AMF Regulated Information
SEC Filings
Convertible bonds
Pre-financed vouchers (PFW)
Obligations Hexagon
Contact for Investors
Contact
EN
FR